期刊文献+

研究肿瘤坏死因子-α和白细胞介素-6对接受不同治疗的绝经后女性C-反应蛋白的影响

Influences of tumor necrosis factor-α and interleukin-6 in effects of different therapy on C-reactive protein in postmenopausal women
下载PDF
导出
摘要 目的 :研究肿瘤坏死因子 α(TNF α)和白细胞介素 6 (IL 6 )对接受雷洛昔芬 (Raloxifene ,RLX)及激素替代治疗(HRT)的绝经后女性C 反应蛋白 (CRP)的影响。方法 :将 390例研究对象随机分为 4个治疗组 ,在试验基线、第 3、6个月分别抽取空腹血样 ,测定CRP、TNF α、IL 6等的含量。结果 :从基线到第 6个月 (终点 )HRT组CRP水平明显升高 (P <0 0 0 1) ,RLX6 0组和RLX 12 0组CRP水平无明显变化 ( P >0 0 5 )。所有治疗组与安慰剂组比较 ,TNF α水平明显降低 ( P <0 0 1) ,而IL 6水平变化的差异没有显著性 (P >0 0 5 )。结论 :HRT和RLX对绝经后女性血清CRP水平产生的作用相反 ,HRT使CRP水平升高 ,而RLX使之降低 ,但不明显。血清CRP水平与TNF α和IL 6相关。 Objective:To explore the influences of tumor necrosis factor-α(TNF-α) and interleukin-6(IL-6) in the effects of hormone replacement therapy(HRT) and raloxifene(RLX) on C-reactive protein(CRP) in postmenopausal women.Methods:390 women were randomly assigned to 4 therapy groups.Group 1:raloxifene HCl 60 mg/day(RLX60);Group 2:raloxifene HCl 120 mg/day(RLX 120);Group 3:HRT;Group 4:placebo.The baseline,3-and 6-month fasting blood samples were obtained from the women.Serum CRP,TNF-α,IL-6,etc were measured in the original trial and a subsequent study,respectively.Results:CRP levels increased significantly from baseline to 6 months in the HRT group(P<0.001);CRP levels decreased nonsignificiantly in the RLX 60 and RLX 120 groups(P>0.05);TNF-α levels decreased significantly in each treatment group compared with placebo group(P<0.01),and the differences of IL-6 levels were not significantly in each treatment group compared with placebo group(P>0.05).Conclusion:The opposite effects of HRT and raloxifene on CRP in postmenopausal women.HRT-induced increase in CRP levels,and RLX-induced decrease nonsignificantly in CRP levels.Serum CRP levels were correlated to IL-6 and TNF-α. [
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2003年第5期357-358,366,共3页 Chinese Journal of Immunology
  • 相关文献

参考文献9

  • 1Cushman M, Meilahn E N, Psaty B M et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women [ J ]. Arterioscler Thromb Vasc Biol, 1999; 19:893.
  • 2Ridker P M, Hermekens C H, Rifai N et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein[J]. Ciroalation,1999;100:713.
  • 3Van Baal W M, Kenemans P,Van der Mooren M J et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women[J] .Thromb Haemost, 1999;81:925.
  • 4Ridker P M, Hennekens C H, Buring J E et al. C-reactive protein and other markers of inflammation in the predication of cardiovascular disease in women[J]. N Engl J Med.2000;342:836.
  • 5Ridker P M,Rifai N, Pfeffer M et al. Elevation of tumor necrosis factoralpha and increased risk of recurrent coronary events after myocardial infarction[J]. Circulation, 2000; 101:2149.
  • 6Ridker P M,Rifal N,Stampfer M J et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men[J]. Circulation,2000; 101 : 1767.
  • 7Walsh B W,Paul S,Wild R A et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial[ J ]. J Endocrinol Metabol,2000; 85: 214.
  • 8Blum A, Schenke W H, Hathaway L et al. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of1 inflammation in postmenopausal women[J] .Am J Cardiol,2000;86:892.
  • 9Giltay E J, Gooren L J, Emeis J J et al. Oral ethinyl estradiol, but not transdermal 17 beta-estradiol,increases plasma C-reactive protein levels in men[letter] [J]. Thromb Haemost,2000;84:359.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部